Seminars in Oncology
Volume 30, Issue 3 , Pages 369-374 , June 2003

Close monitoring and lifetime follow-up is optimal for patients with a history of melanoma

  • David F. Christianson

      Affiliations

    • Department of Internal Medicine, University of Missouri Health Care, Ellis Fischel Cancer Center, Columbia, MO, USA
    • ,
  • Clay M. Anderson

      Affiliations

    • Department of Internal Medicine, University of Missouri Health Care, Ellis Fischel Cancer Center, Columbia, MO, USA
    • *Address reprint requests to Clay Anderson, MD, Department of Internal Medicine-Hematology/Oncology, University of Missouri Health Care, Ellis Fischel Cancer Center, Business Loop 70 West, Columbia, MO 65203 USA

References 

  1. Poo-Hwu WJ, Ariyan S, Lamb L, et al.  Follow-up recommendations for patients with American Joint Commission on Cancer stages I-III malignant melanoma. Cancer. 1999;86:2252–2258
  2. Sober AJ, Tsu-yi C, Duvic M, et al.  Guidelines of care for primary cutaneuos melanoma. J Am Acad Dermatol. 2001;45:579–586
  3. Romero JB, Stefanato CM, Kopf AW, et al.  Follow-up recommendations for patients for patients for patients with stage I malignant melanoma. J Dermatol Surg Oncol. 1994;20:175–178
  4. McCarthy WH, Shaw HM, Thompson JF, et al.  Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet. 1988;166:497–502
  5. Reintgen DS, Cox C, Slingluff CL, et al.  Recurrent malignant melanoma: The identification of prognostic indicators to predict survival. Ann Plast Surg. 1992;28:45–49
  6. Ross MI. Staging evaluation and surveillance for melanoma patients in a fiscally restrictive medical environment. Surg Clin North Am. 1996;76:1423–1432
  7. Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol. 1985;13:756–760
  8. Brobeil A, Rapaport D, Wells K, et al.  Multiple primary melanomas: Implications for screening and follow-up programs for melanoma. Ann Surg Oncol. 1997;4:19–23
  9. Garbe C, Paul A, Kohler-Spath H, et al.  Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520–529
  10. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century. J Am Acad Dermatol. 1997;34:839–847
  11. Jemal A, Thomas A, Murray T, et al.  Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23–47
  12. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance: Patient or physician based?. Ann Surg. 1995;221:566–569
  13. Weiss M, Loprinzi CL, Creagan ET, et al.  Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274:1703–1705
  14. Balch CM, Buzaid AC, Soong SJ, et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648
  15. Schmid-Wendtner M, Baumert J, Schmidt M, et al.  Late metastases of cutaneous melanoma: An analysis of 31 patients. J Am Acad Dermatol. 2000;43:605–609
  16. Shaw HM, Beattie CW, McCarthy WH, et al.  Late relapse from cutaneous stage I malignant melanoma. Arch Surg. 1985;120:1155–1159
  17. McEwan L, Smith JG, Matthews JP. Late recurrence of localized cutaneous melanoma: its influence on follow-up policy. Plast Reconstr Surg. 1990;86:527–534
  18. DiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer. 2001;91:1520–1524
  19. Difronzo LA, Wanek LA, Elashoff R, et al.  Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol. 1999;6:705–711
  20. Tafra L, Dale PS, Wanek LA, et al.  Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg. 1995;110:119–129
  21. Petit T, Borel C, Rixe O, et al.  Complete remission seven years after treatment for metastatic melanoma. Cancer. 1996;777:900–902
  22. Ricaniadis N, Konstadoulakis MM, Walsh D, et al.  Gastrointestinal metastases from malignant melanoma. Surg Oncol. 1995;4:105–111
  23. Overett TK, Shiu MH. Surgical treatment of distant metastases: Indications and results. Cancer. 1985;56:1222–1230
  24. Sasson HN, Poo WJ, Henderson-Bakas M, et al.  Prolonged survival in patients with advanced melanoma treated with neoadjuvant chemotherapy followed by resection. Ann Plast Surg. 1996;37:286–292
  25. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol. 1997;24:S39–S43
  26. Legha SS, Ring S, Bedikian A, et al.  Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon alpha. Ann Oncol. 1996;7:827–835
  27. White RR, Stanley WE, Johnson JL, et al.  Long-term survival in 2505 patients with melanoma with regional lymph node metastasis. Ann Surg. 2002;235:879–887
  28. Kirkwood JM, Strawderman MH, Ernstoff MS, et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol. 1996;14:7–17
  29. Soong S-J, Harrison RA, McCarthy WH, et al.  Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol. 1998;67:228–233
  30. Balch CM, Soong SJ, Gershenwald JE, et al.  Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–3634
  31. In:  eds Greene FL,  Page DL,  Fleming ID, et al. editor. In AJCC (American Joint Committee on Cancer) Cancer Staging Manual. New York, NY: Springer-Verlag,; 2002;p. 211–212
  32. Pearlman NW, Takach TJ, Robinson WA, et al.  A case-control study of late recurrence of malignant melanoma. Am J Surg. 1992;164:458–461
  33. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer)of cutaneous melanoma. Cancer. 1997;79:2361–2370
  34. Finck SJ, Giuliano AE, Morton DL. LDH and melanoma. Cancer. 1983;51:840–843
  35. Balch CM, Houghton AN. Diagnosis of metastatic melanoma at distant sites. In Cutaneous Melanoma. In:  eds Balch CM,  Houghton AN,  Milton GW, et al. editor. Philadelphia, PA: Lippincott,; 1992;p. 439–467
  36. Boni R, Huch Boni RA, Steinerty H, et al.  Anti-melanoma monoclonal antibody 225.28s immunoscintigraphy in metastatic melanoma. Dermatology. 1995;191:119–123
  37. Blend MJ, Hyun H, Patel B, et al.  Radioimmunoscintigraphy in patients with early stage cutaneous malignant melanoma. J Nucl Med. 1996;37:252–257
  38. Steinert HC, Huch Boni RA, Buck A, et al.  Malignant melanoma: Staging with whole-body positron emission topography and (2-fL-18)-fluoro-2-deoxy-D-glucose. Radiology. 1995;195:705–709
  39. Boni R, Huch-Boni RA, Steinert H, et al.  Early detection of melanoma metastasis using fludeoxyglucose F 18 positron emission topography. Arch Dermatol. 1996;132:875–876
  40. Wagner JD, Schauwecker D, Hutchins G, et al.  Initial assessment of positron emission topography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol. 1997;64:181–189
  41. Hara H, Walsh N, Yamada K, et al.  High plasma level of eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker for malignant melanoma. J Invest Dermatol. 1994;102:501–505
  42. Yamada K, Walsh N, Hara H, et al.  Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases. Arch Dermatol. 1992;128:491–494
  43. Faraj BA, Camp VM, Murray DR, et al.  Plasma L-dopa in the diagnosis of malignant melanoma. Clin Chem. 1986;32:159–161
  44. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with Stage III melanoma. Ann Surg Oncol. 1997;4:252–258
  45. Ariyan S, Poo WJ, Bolognia JL, et al.  Multiple primary melanomas: Data and significance. Plast Reconstr Surg. 1995;96:1384–1389
  46. Koh HK, Caruso A, Gage I, et al.  Evaluationof melanoma/skin cancer screening in Massachusetts: Preliminary results. Cancer. 1990;65:375–379
  47. Grin CM, Kopfn AW, Welkovich B, et al.  Accuracy in the clinical diagnosis of malignant melanoma. Arch Dermatol. 1990;126:763–766
  48. Ramsay DL, Fox AB. The ability of primary care physicians to recognize the common dermatoses. Arch Dermatol. 1981;117:620–622
  49. Cassileth BR, Clark WH, Luek ET, et al.  How well do physicians recognize melanoma and other problem lesions?. J. Am Acad Dermatol. 1986;14:555–560
  50. Kang S, Barnhill RL, Minn MC, et al.  Multiple primary cutaneous melanomas. Cancer. 1992;70:1911–1916
  51. Reider-Growasser I, Merimsky O, Karminsky N, et al.  Computed tomography features of cerebral spread of malignant melanoma. Am J Clin Oncol. 1996;19:49–53

PII: S0093-7754(03)00097-6

Seminars in Oncology
Volume 30, Issue 3 , Pages 369-374 , June 2003

Article Tools